Sonya Reid
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Vanderbilt Training Program in Molecular and Genetic Epidemiology of Cancer
Open Date: 2017-09-01
Close Date: 2022-08-31
Articles (12)
Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.
Year:
2025
Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).
Year:
2025
PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).
Year:
2025
Supplementary Figure 2: MHC-I and MHC-II expression is higher in Stage I/II, premenopausal patients. The relative frequency difference of tumors having (A) high MHC-I expression and (B) ≥ 5% tumor cells expressing MHC-II are compared between stage and menopausal status . Relative frequency difference calculated using Stage I/II and premenopausal as control condition, with negative RFD representing frequency higher in Stage I/II or premenopausal patients. Bootstrap method used to generate standard errors.
Year:
2024
Purpose: Immunotherapy (IO) in triple-negative breast cancer (TNBC) has improved survival outcomes, with promising improvements in pCR rates among early high-risk hormone receptor (HR)+/HER2− breast cancers. However, biomarkers are needed to select patients likely to benefit from IO. MHC-I and tumor-specific MHC-II (tsMHC-II) expression are candidate biomarkers for PD-(L)1 checkpoint inhibition but existing data from clinical trials included limited racial/ethnic diversity. Experimental Design: We performed multiplexed immunofluorescence assays in the Carolina Breast Cancer Study (CBCS; n = 1,628, 48% Black, 52% non-Black). Intrinsic subtype and P53 mutant-like status were identified using RNA-based multigene assays. We ranked participants based on tumoral MHC-I intensity (top 33% categorized as “MHC-I h igh ”) and MHC-II+ (≥5% of tumor cells as tsMHC-II+). MHC-I/II were evaluated in association with clinicopathological features by race. Results: Black participants had higher frequency of TNBC (25% vs. 12.5%, P ≤ 0.001) and basal-like (30% vs. 14%, P ≤ 0.001) tumors overall, and higher frequency of basal-like (11% vs. 5.5%, P = 0.002) and TP53 mutant tumors (26% vs. 17%, P = 0.002) among HR+/HER2−. The frequency of tsMHC-II+ was higher in HR+/HER2− Black participants (7.9% vs. 4.9%, P = 0.04). Black participants also had higher frequency of MHC-I high (38.7% vs. 28.2%, P P = 0.02). Conclusions: In this diverse study population, MHC-I and MHC-II tumor cell expression were more highly expressed in HR+/HER2− tumors from Black women, underscoring the importance of diverse and equitable enrollment in future IO trials.
Year:
2024
Supplementary Figure 1: MHC-I and MHC-II expression is associated with Race. The log10(n+1) normalized (A) percentage of MHC-I+ tumor cells and (B) percentage of MHC-II+ tumor cells are compared between Black and Non-Black patients. Student t-test was used.
Year:
2024
Supplementary Figure 2: MHC-I and MHC-II expression is higher in Stage I/II, premenopausal patients. The relative frequency difference of tumors having (A) high MHC-I expression and (B) ≥ 5% tumor cells expressing MHC-II are compared between stage and menopausal status . Relative frequency difference calculated using Stage I/II and premenopausal as control condition, with negative RFD representing frequency higher in Stage I/II or premenopausal patients. Bootstrap method used to generate standard errors.
Year:
2024
Supplementary Figure 1: MHC-I and MHC-II expression is associated with Race. The log10(n+1) normalized (A) percentage of MHC-I+ tumor cells and (B) percentage of MHC-II+ tumor cells are compared between Black and Non-Black patients. Student t-test was used.
Year:
2024
Purpose: Immunotherapy (IO) in triple-negative breast cancer (TNBC) has improved survival outcomes, with promising improvements in pCR rates among early high-risk hormone receptor (HR)+/HER2− breast cancers. However, biomarkers are needed to select patients likely to benefit from IO. MHC-I and tumor-specific MHC-II (tsMHC-II) expression are candidate biomarkers for PD-(L)1 checkpoint inhibition but existing data from clinical trials included limited racial/ethnic diversity. Experimental Design: We performed multiplexed immunofluorescence assays in the Carolina Breast Cancer Study (CBCS; n = 1,628, 48% Black, 52% non-Black). Intrinsic subtype and P53 mutant-like status were identified using RNA-based multigene assays. We ranked participants based on tumoral MHC-I intensity (top 33% categorized as “MHC-I h igh ”) and MHC-II+ (≥5% of tumor cells as tsMHC-II+). MHC-I/II were evaluated in association with clinicopathological features by race. Results: Black participants had higher frequency of TNBC (25% vs. 12.5%, P ≤ 0.001) and basal-like (30% vs. 14%, P ≤ 0.001) tumors overall, and higher frequency of basal-like (11% vs. 5.5%, P = 0.002) and TP53 mutant tumors (26% vs. 17%, P = 0.002) among HR+/HER2−. The frequency of tsMHC-II+ was higher in HR+/HER2− Black participants (7.9% vs. 4.9%, P = 0.04). Black participants also had higher frequency of MHC-I high (38.7% vs. 28.2%, P P = 0.02). Conclusions: In this diverse study population, MHC-I and MHC-II tumor cell expression were more highly expressed in HR+/HER2− tumors from Black women, underscoring the importance of diverse and equitable enrollment in future IO trials.
Year:
2024
Year:
2020
Year:
2020
Year:
2020
Collaborators (16)
Carolina Reduzzi
Assistant Professor
Weill Cornell Medicine
Priyanka Sharma
Associate Professor
University of Kansas Medical Center
Charles Perou
Professor
University of North Carolina
Laura Kennedy
Assistant Professor
Vanderbilt University Medical Center
Angela DeMichele
University of Pennsylvania
Justin M. Balko
Vanderbilt University Medical Center
Cynthia X. Ma
Washington University in Saint Louis School of Medicine
Yara G Abdou
University of North Carolina at Chapel Hill
Harold Burstein
Professor
Dana-Farber Cancer Institute
Xiaopeng Sun
Vanderbilt University
Melissa A. Troester
Professor
University of North Carolina at Chapel Hill
Rubina Qamar
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Kathy Miller
Indiana University Bloomington
Erica Mayer
Dana-Farber Cancer Institute
Massimo Cristofanilli
Professor of Medicine
Weill Cornell Medicine
Reshma Mahtani
Chief of Breast Medical Oncology
Sylvester Comprehensive Cancer Center, University of Miami
Make your next move.
Prepare your application
Review drafts before you send them.